NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
(148.56) (173.05) (136.23) (177.65)

+8 more TTM periods

Depreciation & Amortization
0.95 (3.78) (8.61) (12.65)
Non Cash Items (Other)
134.38 150.37 115.88 156.01
Accounts Receivable Change
(18.63) (29.50) (38.94) (32.85)
Change in inventories
(3.01) (4.50) (5.67) (0.25)
Change in payables and accrued liability
30.95 30.26 18.96 30.87
Change in other assets and liabilities
1.11 3.32 5.57 2.05
Operating Cash Flow
(2.81) (26.88) (49.03) (34.48)
Capital expenditures
(22.62) (21.19) (26.65) (30.69)
Short Term Investments Change (Net)
431.75 472.68 463.92 109.43
Investing cash flow
409.13 451.50 437.28 78.74
Repayment/Issuance of Debt (Net)
— — (460.97) 183.99
Equity Repurchase (Common, Net)
7.07 4.91 9.77 10.86
Other financial activities
20.46 49.18 84.76 —
Financing cash flow
(454.59) (456.76) (451.34) 110.84
Exchange Rate Adjustment
(0.24) 0.04 0.39 0.34
Change in Cash
(48.51) (32.11) (62.70) 155.44
Beginning Cash
103.39 103.39 166.09 166.09
Ending Cash
54.88 71.28 103.39 321.53
Stock Based Compensation
129.16 138.29 104.83 147.77
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
10.41 (0.43) (20.07) (0.19)
Investments Change (Net)
431.75 472.68 463.92 109.43
Issuance/Purchase of Shares
7.07 4.91 9.77 10.86

Fold the line items

In millions of $ except per-share values · columns are period end dates